Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment

Androgen receptor (AR) antagonists, such as enzalutamide, have had a major impact on the treatment of metastatic castration-resistant prostate cancer (CRPC). However, even with the advent of AR antagonist therapies, patients continue to develop resistance, and new strategies to combat continued AR s...

Full description

Saved in:

Bibliographic Details
Published in:	Neoplasia (New York, N.Y.) Vol. 22; no. 2; pp. 111 - 119
Main Authors:	Kregel, Steven, Wang, Chao, Han, Xin, Xiao, Lanbo, Fernandez-Salas, Ester, Bawa, Pushpinder, McCollum, Brooke L., Wilder-Romans, Kari, Apel, Ingrid J., Cao, Xuhong, Speers, Corey, Wang, Shaomeng, Chinnaiyan, Arul M.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.02.2020 Neoplasia Press Elsevier
Subjects:	Androgen Receptor Antagonists - pharmacology Androgens - genetics Androgens - metabolism Animals Benzamides - pharmacology Cell Line, Tumor Cell Proliferation - drug effects Drug Resistance, Neoplasm - genetics Gene Expression Regulation, Neoplastic - drug effects Humans Male Mice Nitriles - pharmacology Original article Phenylthiohydantoin - pharmacology Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - genetics Prostatic Neoplasms, Castration-Resistant - pathology Receptors, Androgen - drug effects Receptors, Androgen - genetics Xenograft Model Antitumor Assays
ISSN:	1476-5586, 1522-8002, 1476-5586
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!